Dihydrocodeine Bitartrate

CHEMBL2062266 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

451.5 g/mol

LogP

—

Phase

4

The bitartrate salt form of dihydrocodeine, used in oral liquid and tablet preparations for pain relief and cough suppression. As a semi-synthetic opioid, it binds to opioid receptors in the brain and spinal cord to reduce pain perception. It is subject to the same abuse potential and dependency risks as other opioid analgesics.

Masse moléculaire

451,5000 g/mol

TPSA

157,00 Å²

Aires thérapeutiques

Pain Management Chronic Pain

Mécanisme d'action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O

InChI

InChI=1S/C18H23NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,13-,17-,18-;/m0./s1

Molecular Formula

C22H29NO9

HBD / HBA

5 / 10

Liaisons Rotatives

4

Atomes Lourds

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The bitartrate salt form of dihydrocodeine, used in oral liquid and tablet preparations for pain relief and cough suppression. As a semi-synthetic opioid, it binds to opioid receptors in the brain and spinal cord to reduce pain perception. It is subject to the same abuse potential and dependency risks as other opioid analgesics.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dihydrocodeine Bitartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2062266. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5492624. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Dihydrocodeine Bitartrate sur PillFYI

Structure

Données Clés

Formule: C22H29NO9
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.